The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the […]
The ISPOR 23rd Annual International Meeting took place in Baltimore, Maryland from May 19-23, and Precision Health Economics (PHE) and Precision Xtract were both there to meet with you and share our expertise. […]
Lessons Learned from the Oncology Care Model Implementation: Maximizing the Value of Health Economics Evidence—presented by PHE Senior Economist and former Congressional Budget Office Deputy Assistant Director, Dr. James Baumgardner, and PHE Scientific Advisor, Dr. Wade Aubry, former Chief Medical Officer of Blue Shield of California. […]
This unique webinar addresses current standards of cost-effectiveness analysis- including limitations and challenges- and reviews often overlooked sources of value and the importance of these alternative value assessments in discussions with payers, policymakers, and other stakeholders (w/Q&A session following webinar presentation). […]
For more information, or to learn how to change your cookies preferences, please click here.